Erratum: Results from the phase III randomized trial of onartuzumab plus erlotinib versus erlotinib in previously treated stage IIIB or IV non-small-cell lung cancer: METLung (Journal of Clinical Oncology (2017) DOI: 10.1200/JCO.2016.69.2160)

David R. Spigel; Martin J. Edelman; Kenneth O’Byrne; Luis Paz-Ares; Simonetta Mocci; See Phan; David S. Shames; Dustin Smith; Virginia E. Paton; Tony Mok

doi:10.1200/JCO.2018.78.0783

Erratum: Results from the phase III randomized trial of onartuzumab plus erlotinib versus erlotinib in previously treated stage IIIB or IV non-small-cell lung cancer: METLung (Journal of Clinical Oncology (2017) DOI: 10.1200/JCO.2016.69.2160)

David R. Spigel, Martin J. Edelman, Kenneth O’Byrne, Luis Paz-Ares, Simonetta Mocci, See Phan, David S. Shames, Dustin Smith, Virginia E. Paton, Tony Mok

Research output: Contribution to journal › Comment/debate

Abstract

The February 1, 2017, article by Spigel et al, entitled "Results From the Phase III Randomized Trial of Onartuzumab Plus Erlotinib Versus Erlotinib in Previously Treated Stage IIIB or IV Non-Small-Cell Lung Cancer: METLung" (J Clin Oncol 10.1200/JCO.2016.69.2160), was published with an error. Under Affiliations, Luis Paz-Ares' information should have included University of Seville.This has been corrected as of February 7, 2018. The authors apologize for the error.

Original language	English
Pages (from-to)	833
Number of pages	1
Journal	Journal of Clinical Oncology
Volume	36
Issue number	8
DOIs	https://doi.org/10.1200/JCO.2018.78.0783
State	Published - Mar 10 2018
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1200/JCO.2018.78.0783

Fingerprint

Dive into the research topics of 'Erratum: Results from the phase III randomized trial of onartuzumab plus erlotinib versus erlotinib in previously treated stage IIIB or IV non-small-cell lung cancer: METLung (Journal of Clinical Oncology (2017) DOI: 10.1200/JCO.2016.69.2160)'. Together they form a unique fingerprint.

Cite this

Spigel, D. R., Edelman, M. J., O’Byrne, K., Paz-Ares, L., Mocci, S., Phan, S., Shames, D. S., Smith, D., Paton, V. E., & Mok, T. (2018). Erratum: Results from the phase III randomized trial of onartuzumab plus erlotinib versus erlotinib in previously treated stage IIIB or IV non-small-cell lung cancer: METLung (Journal of Clinical Oncology (2017) DOI: 10.1200/JCO.2016.69.2160). Journal of Clinical Oncology, 36(8), 833. https://doi.org/10.1200/JCO.2018.78.0783

Spigel, David R. ; Edelman, Martin J. ; O’Byrne, Kenneth et al. / Erratum : Results from the phase III randomized trial of onartuzumab plus erlotinib versus erlotinib in previously treated stage IIIB or IV non-small-cell lung cancer: METLung (Journal of Clinical Oncology (2017) DOI: 10.1200/JCO.2016.69.2160). In: Journal of Clinical Oncology. 2018 ; Vol. 36, No. 8. pp. 833.

@article{bc33dfbda08d4a90b201d1dc547e44e7,

title = "Erratum: Results from the phase III randomized trial of onartuzumab plus erlotinib versus erlotinib in previously treated stage IIIB or IV non-small-cell lung cancer: METLung (Journal of Clinical Oncology (2017) DOI: 10.1200/JCO.2016.69.2160)",

abstract = "The February 1, 2017, article by Spigel et al, entitled {"}Results From the Phase III Randomized Trial of Onartuzumab Plus Erlotinib Versus Erlotinib in Previously Treated Stage IIIB or IV Non-Small-Cell Lung Cancer: METLung{"} (J Clin Oncol 10.1200/JCO.2016.69.2160), was published with an error. Under Affiliations, Luis Paz-Ares' information should have included University of Seville.This has been corrected as of February 7, 2018. The authors apologize for the error.",

author = "Spigel, {David R.} and Edelman, {Martin J.} and Kenneth O{\textquoteright}Byrne and Luis Paz-Ares and Simonetta Mocci and See Phan and Shames, {David S.} and Dustin Smith and Paton, {Virginia E.} and Tony Mok",

year = "2018",

month = mar,

day = "10",

doi = "10.1200/JCO.2018.78.0783",

language = "English",

volume = "36",

pages = "833",

journal = "Journal of Clinical Oncology",

issn = "0732-183X",

publisher = "Lippincott Williams and Wilkins",

number = "8",

}

Spigel, DR, Edelman, MJ, O’Byrne, K, Paz-Ares, L, Mocci, S, Phan, S, Shames, DS, Smith, D, Paton, VE & Mok, T 2018, 'Erratum: Results from the phase III randomized trial of onartuzumab plus erlotinib versus erlotinib in previously treated stage IIIB or IV non-small-cell lung cancer: METLung (Journal of Clinical Oncology (2017) DOI: 10.1200/JCO.2016.69.2160)', Journal of Clinical Oncology, vol. 36, no. 8, pp. 833. https://doi.org/10.1200/JCO.2018.78.0783

Erratum: Results from the phase III randomized trial of onartuzumab plus erlotinib versus erlotinib in previously treated stage IIIB or IV non-small-cell lung cancer: METLung (Journal of Clinical Oncology (2017) DOI: 10.1200/JCO.2016.69.2160). / Spigel, David R.; Edelman, Martin J.; O’Byrne, Kenneth et al.
In: Journal of Clinical Oncology, Vol. 36, No. 8, 10.03.2018, p. 833.

Research output: Contribution to journal › Comment/debate

TY - JOUR

T1 - Erratum

T2 - Results from the phase III randomized trial of onartuzumab plus erlotinib versus erlotinib in previously treated stage IIIB or IV non-small-cell lung cancer: METLung (Journal of Clinical Oncology (2017) DOI: 10.1200/JCO.2016.69.2160)

AU - Spigel, David R.

AU - Edelman, Martin J.

AU - O’Byrne, Kenneth

AU - Paz-Ares, Luis

AU - Mocci, Simonetta

AU - Phan, See

AU - Shames, David S.

AU - Smith, Dustin

AU - Paton, Virginia E.

AU - Mok, Tony

PY - 2018/3/10

Y1 - 2018/3/10

N2 - The February 1, 2017, article by Spigel et al, entitled "Results From the Phase III Randomized Trial of Onartuzumab Plus Erlotinib Versus Erlotinib in Previously Treated Stage IIIB or IV Non-Small-Cell Lung Cancer: METLung" (J Clin Oncol 10.1200/JCO.2016.69.2160), was published with an error. Under Affiliations, Luis Paz-Ares' information should have included University of Seville.This has been corrected as of February 7, 2018. The authors apologize for the error.

AB - The February 1, 2017, article by Spigel et al, entitled "Results From the Phase III Randomized Trial of Onartuzumab Plus Erlotinib Versus Erlotinib in Previously Treated Stage IIIB or IV Non-Small-Cell Lung Cancer: METLung" (J Clin Oncol 10.1200/JCO.2016.69.2160), was published with an error. Under Affiliations, Luis Paz-Ares' information should have included University of Seville.This has been corrected as of February 7, 2018. The authors apologize for the error.

UR - http://www.scopus.com/inward/record.url?scp=85043510118&partnerID=8YFLogxK

U2 - 10.1200/JCO.2018.78.0783

DO - 10.1200/JCO.2018.78.0783

M3 - Comment/debate

AN - SCOPUS:85043510118

SN - 0732-183X

VL - 36

SP - 833

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

IS - 8

ER -

Spigel DR, Edelman MJ, O’Byrne K, Paz-Ares L, Mocci S, Phan S et al. Erratum: Results from the phase III randomized trial of onartuzumab plus erlotinib versus erlotinib in previously treated stage IIIB or IV non-small-cell lung cancer: METLung (Journal of Clinical Oncology (2017) DOI: 10.1200/JCO.2016.69.2160). Journal of Clinical Oncology. 2018 Mar 10;36(8):833. doi: 10.1200/JCO.2018.78.0783

Erratum: Results from the phase III randomized trial of onartuzumab plus erlotinib versus erlotinib in previously treated stage IIIB or IV non-small-cell lung cancer: METLung (Journal of Clinical Oncology (2017) DOI: 10.1200/JCO.2016.69.2160)

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this